Revolutionary Step in B2B: The First Verified & Trusted Pharma, Surgical & Medical Trade Automation Platform • Direct Factory Deals, Global Tenders & 7-Document Export Dossiers•Revolutionary Step in B2B: The First Verified & Trusted Pharma, Surgical & Medical Trade Automation Platform • Direct Factory Deals, Global Tenders & 7-Document Export Dossiers•
Price & Customs Tariff Updates

WTO World Tariff Profiles 2026: MFN Duty Rates for HS Chapter 29 APIs vs. HS Chapter 30 Medicaments

Cross-border trade and customs duty analysis based on the 2026 World Tariff Profiles covering Active Pharmaceutical Ingredients (HS Chapter 29, including 2941.10 penicillins and 2936.27 ascorbic acid) versus Finished Dosage Forms (HS Chapter 30, including 3004.20 and 3004.90).

  • Bound vs. Applied Tariffs: Pharmaceutical Agreement signatories maintain 0% MFN duty on designated INN molecules and intermediates; emerging import markets apply 5%–15% protective tariffs on finished retail packs while keeping raw APIs at 0%–5%.
  • Customs Declaration: Exporters must cite accurate 6-to-8 digit HS subheadings and attach INN (International Nonproprietary Name) chemical designations on Commercial Invoices to prevent misclassification surcharges.

Official Source & Verification Reference

Issuing Authority: World Trade Organization (WTO) Tariff & Trade Data • Reference: WTO-WTP-2026-CH29-30

Verify Official Source Document ↗
WTO World Tariff Profiles 2026: MFN Duty Rates for HS Chapter 29 APIs vs. HS Chapter 30 Medicaments | PharmaTrade Online Market Bulletin | PharmaTrade Online